HC Wainwright restated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX - Free Report) in a report published on Friday,Benzinga reports. They currently have a $20.00 price target on the stock.
Poseida Therapeutics Stock Up 5.1 %
Poseida Therapeutics stock traded up $0.15 during mid-day trading on Friday, hitting $3.08. The company had a trading volume of 1,255,667 shares, compared to its average volume of 559,640. The business has a fifty day moving average of $2.76 and a 200 day moving average of $2.87. The company has a quick ratio of 2.48, a current ratio of 2.48 and a debt-to-equity ratio of 0.97. Poseida Therapeutics has a 1 year low of $1.87 and a 1 year high of $4.27. The stock has a market cap of $299.16 million, a price-to-earnings ratio of -2.59 and a beta of 0.54.
Hedge Funds Weigh In On Poseida Therapeutics
Several institutional investors have recently added to or reduced their stakes in PSTX. Intech Investment Management LLC purchased a new stake in Poseida Therapeutics in the 3rd quarter valued at approximately $46,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Poseida Therapeutics by 62.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company's stock valued at $1,027,000 after acquiring an additional 138,510 shares during the period. Privium Fund Management B.V. acquired a new position in shares of Poseida Therapeutics during the 3rd quarter worth $222,000. SG Americas Securities LLC purchased a new stake in shares of Poseida Therapeutics during the 3rd quarter worth approximately $70,000. Finally, Mackenzie Financial Corp acquired a new stake in Poseida Therapeutics in the second quarter valued at $51,000. Institutional investors and hedge funds own 46.87% of the company's stock.
About Poseida Therapeutics
(
Get Free Report)
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Featured Stories
Before you consider Poseida Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Poseida Therapeutics wasn't on the list.
While Poseida Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
